GeneAb™ BRAF V600E [IHC600] on Thyroid Papillary Carcinoma with the BRAF V600E Mutation
GeneAb™ BRAF V600E [IHC600] on Thyroid Papillary Carcinoma with the BRAF V600E Mutation
BRAF V600E

CAT. NO. IHC600
FORMAT
VOLUME
PRICE
N/A
QUANTITY
<
1
<
*The listed price is an estimate only.
Description

Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.

Documents
DATASHEETS
OTHERS
Specifications

CLONE:
IHC600

ISOTYPE:
IgG2b

HOST SPECIES:
Mouse

CLONALITY:
Monoclonal

POSITIVE CONTROL:
Colorectal Adenocarcinoma, Thyroid Papillary Carcinoma with the BRAF V600E Mutation

DILUTION RANGE:
1:200

INTENDED USE/REG. STATUS:
CE-IVD


Customer Reviews
No customer reviews.